Using multiomic data to predict postoperative complications after major surgery in the UK Biobank cohort

Richard A. Armstrong,[1] Paul Yousefi,[1,2] Ben Gibbison,[2,3] Golam M Khandaker,[1,2,4,5] Tom R Gaunt[1,2]

1. MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK.
2. NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
3. Bristol Medical School, University of Bristol, Bristol, UK.
4. Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.
5. Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Correspondence to: Richard A Armstrong

Email: ra17848@bristol.ac.uk

Keywords: peri-operative risk prediction; multiomics; biobank; postoperative complications

X: @drrichstrong

* Part of this work was presented at the Association of Anaesthetists Winter Scientific Meeting 2026, 15-16 January 2026, QEII Centre, Westminster, London. Abstract: Anaesthesia 2026;81:S7-S63. https://doi.org/10.1111/anae.70103.

Short title: Multiomics and postoperative complications

Summary

Introduction

Postoperative complications after major surgery have substantial impacts on morbidity and resource utilisation. We investigated whether adding high-dimensional metabolomic and proteomic data to standard clinical variables would improve the prediction of a range of postoperative complications.

Methods

We analysed data from UK Biobank, a large prospective cohort study. Participants who underwent major surgery and had metabolomic and/or proteomic data were included. The primary outcomes were postoperative atrial fibrillation, acute kidney injury, acute myocardial infarction, delirium, stroke and surgical site infection. We trained machine learning models (elastic net penalised regression) with a range of feature sets to predict these outcomes. For outcomes where sample sizes were below recommended levels for predictive modelling, we employed transfer learning from the non-postoperative domain. We compared the predictive performance (AUROC, sensitivity, specificity) of models using only baseline clinical variables with those integrating single- and multiomic datasets.

Results

The dataset included 158,156 individuals undergoing qualifying surgery. The numbers of cases with omic data varied across outcome phenotypes and feature sets: metabolomic: 144–1596, proteomic: 27–289 and multiomic: 15–219. Baseline clinical models achieved robust predictive performance (AUROC 0.72–0.88, sensitivity 0.71–0.80). The addition of metabolomic and/or proteomic features, using a variety of integration approaches, provided no clinically meaningful improvement in performance across any of the clinical phenotypes. Transfer learning from the non-postoperative domain improved model performance and stability but did not outperform baseline clinical models.

Conclusions

The addition of metabolomic and/or proteomic data from samples collected at a temporal distance from surgery does not improve pre-operative risk prediction compared to standard clinical variables. The lack of incremental predictive value likely reflects the extended gap between biobank sampling and the surgical event.

The success of transfer learning from non-postoperative settings suggests shared biological risk between chronic and acute phenotypes.

Introduction

Postoperative complications are a major driver of morbidity, mortality and resource utilisation, occurring in up to 15% of patients worldwide [1], and can have serious long-term implications for patients [2–4]. Current pre-operative risk stratification tools rely heavily on demographic factors and clinical scoring systems, for example ASA physical status grade [5,6]. However, these fail to capture the biological heterogeneity of individual patients and typically leave a substantial component of peri-operative risk unaccounted for [7].

One approach to add granularity is the use of high-dimensional molecular assays which provide snapshots of the interplay between genetic predisposition, environmental or lifestyle factors, and subclinical disease states [8,9]. Existing studies in the peri-operative setting have tended to study small cohorts, often in a single centre, with a focus on single omics in isolation and little interrogation of whether these investigations add incremental benefit over existing clinical predictors [9]. Large-scale biobanks offer a means to overcome these limitations, providing the necessary scale to explore multiomic associations across diverse phenotypes. However, a distinctive feature of utilising linked health data from such resources is that molecular sampling is often performed at a timepoint months to years before the surgical event. These historic measurements provide an assessment of baseline biological health and multi-morbidity, potentially preceding clinical diagnosis [10,11]. Nonetheless, as the number of measured biomarkers increases, the curse of dimensionality becomes an additional limitation, particularly with limited sample sizes. One approach to counter this is dimensionality reduction, for example through the use of principal component analysis (PCA) or autoencoders (AEs) [12], which limit the number of features to a lower dimension space. An alternative approach is transfer learning, in which prediction patterns are learned from a related source domain with more abundant data and the resulting models are applied or fine-tuned in the target domain [13].

To explore the use of multiomics in pre-operative risk stratification we therefore defined six clinically important postoperative phenotypes, atrial fibrillation (AF), acute kidney injury (AKI), acute myocardial infarction (AMI), delirium, surgical site infection

(SSI) and stroke, in a large cohort of patients undergoing major surgery in the UK Biobank. We investigated whether the addition of metabolomic and/or proteomic data to baseline clinical predictors improved predictive accuracy and whether transfer learning from related, non-postoperative phenotypes could overcome the limitations of previous studies.

Methods

UK Biobank is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants recruited between 2006 and 2010 (http://www.ukbiobank.ac.uk). Linked health data is available for all participants with follow-up to 2022 [20]. The UK Biobank study was approved by the North-West Multi-centre Research Ethics Committee (reference 21/NW/0157) and all participants provided written informed consent. This research has been conducted under project number 128619.

A subset of UK Biobank participants had metabolomic and/or proteomic assay data available at the time of analysis. Metabolic biomarkers were measured from randomly selected EDTA plasma samples using a high-throughput NMR-based metabolic biomarker profiling platform developed by Nightingale Health Ltd. Proteomic analysis was performed using the Olink Explore platform, a Proximity Extension Assay (PEA). Further details on sample selection and quality control procedures are available from UK Biobank [14,15].

The primary analysis used data from the UK Biobank surgical cohort (defined below) to predict the postoperative complications of interest (Figure 1, ‘direct postoperative modelling’). First, clinical covariates were used to train baseline clinical models for each outcome. Omic models were then trained using metabolomic, proteomic and multiomic data as additional features. The transfer learning analysis used data from the non-surgical UK Biobank cohort to predict non-postoperative outcomes (Figure 1, ‘transfer learning’). First, omic models were trained using clinical covariates with the addition of metabolomic, proteomic and multiomic data for each non-postoperative outcome. Then, to ‘transfer’ the learning, the resulting models were applied to the surgical cohort to generate a risk prediction for each non-postoperative outcome. This predicted risk was then used as a feature in the final transfer models to predict the relevant postoperative complications.

For direct postoperative modelling, eligible participants were those with metabolomic and/or proteomic data available who also underwent major, inpatient surgery after their date of enrolment in UK Biobank. Major surgery was defined by OPCS4 codes

using the Bupa Schedule of Procedures and Abbott classification [16–18]. For AF, AKI, AMI and SSI, participants aged 18 and over at the time of surgery were included. For postoperative delirium and stroke, we restricted the analysis to those aged 60 or over. Exclusion criteria for all phenotypes included a previous diagnosis of the outcome of interest and planned day case surgery (see Supplementary Methods 1 for more detail on phenotype definition and exclusions).

The primary outcome for each complication was a first diagnosis of that condition within 30 days of surgery. Controls were defined as those meeting the inclusion criteria but without the complication occurring within 30 days of surgery. Cases and controls were defined separately for each outcome phenotype using the following International Classification of Diseases, Tenth Revision (ICD-10) codes: atrial fibrillation, I48.9; acute kidney injury, N17; acute myocardial infarction, I21; delirium, F05; stroke, I61/I63/I64; and surgical site infection, T81.4.

The modelling dataset included clinical covariates, metabolomic assay data and proteomic assay data, with the outcome phenotype considered as a binary variable. Clinical covariates were selected to reflect those available to clinicians in routine clinical practice: age, sex, Charlson Comorbidity Index (CCI, coded as a binary variable 0-1 vs ≥2 [19]), admission method (elective or emergency) and operation category (major or complex). Metabolomic data included the 251 measured biomarkers in the Nightingale panel [15] plus the spectrometer (1-9) used for analysis. The Olink proteomic data is comprised of multiple panels [14]. Models were developed using the Inflammation I panel (368 biomarkers), the combination of Inflammation I and Inflammation II (737 biomarkers), and all proteins (2922 biomarkers). Table 1 shows the feature sets used for modelling.

For transfer learning, the non-surgical subset of UK Biobank (i.e. those participants with metabolomic and/or proteomic data available who did not undergo major, inpatient surgery after their date of enrolment in UK Biobank) were used as the source domain to prevent any sample overlap with the postoperative cohort.

For each postoperative complication, a chronic or non-postoperative equivalent phenotype was defined, for example chronic atrial fibrillation or non-postoperative

stroke, using the same ICD-10 codes. For surgical site infection, an alternative diagnosis of ‘infections of the skin and subcutaneous tissue’ (ICD-10 codes L00-L08) was used.

The modelling dataset included clinical covariates, metabolomic assay data and proteomic assay data, with the outcome phenotype considered as a binary variable. Clinical covariates included age, sex and CCI, to align with the postoperative analyses. For cases, age and CCI were calculated at the time of the hospital admission related to the diagnosis. To avoid immortal time bias, incidence density sampling was used to assign follow-up times to controls [20]. In brief, the time interval from UK Biobank enrolment to diagnosis for each case was used to generate a distribution of potential follow-up durations. For each control participant, a follow-up duration was randomly assigned from this distribution with age and CCI taken from the most recent hospital episode at that point (i.e. date of UK Biobank enrolment plus follow-up duration). A case-control ratio of 1:4 was used and models were developed using the same feature sets as in the direct postoperative modelling (Table 1).

Data were preprocessed prior to model development. Variables that were missing in ≥10% of participants were omitted, and individuals with missing data for ≥80% of features were excluded. Clinical numerical variables were centred and scaled after imputation of missing values using the median. Categorical data were one-hot encoded with missing values imputed with a constant (‘missing’).

Multiomic data were prepared for analysis using the metaboprep pipeline (v1.0 [21]) with default parameters. Metabolomic data were logit (for percentages) or log (for other biomarkers) transformed then centred and scaled. Missing values were imputed with the biomarker mean (0). For proteomic data, which is provided by Olink as $\log_2$ normalised protein expression (NPX) values, missing values were imputed with the biomarker mean then rank-based inverse normal transformation was applied. Finally, both metabolomic and proteomic features were clipped at ±10 standard deviations before being passed through a custom autoencoder (AE) for dimension reduction. The AEs were designed as symmetrical ‘bottleneck’ networks, functioning as non-linear feature extractors to compress omic inputs into a 16-dimensional latent space. Architectures were determined through an iterative

empirical search, evaluating performance based on reconstruction loss (minimising mean squared error between input and output, using Principal Component Analysis (PCA) as a baseline benchmark) and generalisability (monitoring the divergence between training and validation loss to limit overfitting). To accommodate the varying dimensionality of different omic feature sets, the depth and width of hidden layers were scaled based on the input data (full specifications for each feature set are in Supplementary Methods 2). The AEs were trained for 20 epochs using the Adam optimiser with a learning rate of 10^{-3} and batch size of 32. For multiomic models (those including both metabolomic and proteomic features) both early and late integration approaches were explored. Early integration combined metabolomic and proteomic data into a single AE; late integration trained separate AEs for metabolomic and proteomic data with the outputs of both entering the classifier models (Supplementary Figure 1).

For direct postoperative modelling (baseline and omic models) the Elastic Net logistic regression algorithm was used for model development as it facilitates simultaneous variable selection and model regularisation by combining LASSO (L1) and ridge (L2) penalty terms. To address the significant class imbalance, we trained the Elastic Net models within a Balanced Bagging Classifier. Each bagging classifier trained 50 base estimators (Elastic Net models) on different randomly selected subsets of the available data, undersampling the majority class to achieve a 1:1 case-control ratio ('balanced'). The predicted probabilities of each base estimator were then averaged to provide the final prediction ('bagging'). This ensemble approach stabilises the coefficient estimates and ensures the model is not biased toward the majority class.

To obtain unbiased performance estimates, the bagging classifiers were trained within an adaptive repeated stratified k-fold cross-validation framework (Supplementary Figure 2). *k*-fold cross-validation splits the dataset into *k* partitions (folds). For each fold, models are trained using the other *k-1* folds and tested on the held-out fold. In repeated *k*-fold cross-validation, this process is repeated multiple times with different splits of the data on each repeat. The average performance across all folds then provides a less biased estimate of generalisation performance. The number of folds and repetitions was dynamically adjusted based on the number

of positive cases (*N*) for each complication and feature set (20 repeats of 3-fold cross-validation for *N* <100; 12 repeats of 5-fold cross-validation for *N* ≥100). Where *N* ≥500, an additional 3-fold inner cross-validation loop was used for hyperparameter tuning (*C* and *L1 ratio*; full grid in Supplementary Methods 3). For *N* <500, no inner cross-validation was performed and hyperparameter values were fixed (*C* 1.0; *L1 ratio* 0.5).

To ensure equitable comparison, a distinct clinical baseline model was developed for each outcome-omic dataset combination (due to differences in available sample size) using identical training/testing partitions, maintained via a fixed random seed. Baseline models included age, sex, CCI, operative category and admission method. Omic models included these clinical variables, plus the relevant omic feature set.

For the transfer learning phase, to transfer from the source (non-postoperative) to the target (postoperative) domain final trained models for each non-postoperative phenotype-dataset combination were used to generate a predicted probability of that outcome for each postoperative participant. The inputs to each model were age, sex, CCI and the relevant omic data. The resulting predicted probabilities were then used alongside admission type and operative category (as they are not applicable in the non-postoperative domain and so not included in the non-postoperative models) to train parsimonious 'transfer' models predicting the postoperative outcomes of interest (Figure 1 and Supplementary Methods 4). These reduced models were trained using logistic regression with an L2 penalty term in the same balanced bagging classifier cross-validation framework described above.

Performance metrics were calculated for each of the 60 outer cross-validation folds (either 20 x 3-fold cross-validation or 12 x 5-fold cross-validation) for each model to estimate generalisation performance. To reflect the potential clinical usage of these models in identifying those at increased risk of complications the primary metrics reported are area under the receiver operating characteristic curve (AUROC), recall (sensitivity) and specificity (calculated as 2*balanced accuracy – recall) at the standard probability threshold of 0.5. To assess the incremental benefit of the added omics features we compared the performance of each model against its related baseline model using the Corrected Resampled t-test [22]. This approach was

selected to account for the lack of independence between folds in our repeated cross-validation design, which otherwise leads to an underestimation of variance and an inflated Type I error rate. To account for multiple hypothesis testing across the different feature sets and model comparisons, p-values were adjusted using the Benjamini-Hochberg False Discovery Rate (FDR) procedure, with statistical significance defined as a FDR < 0.05. Corrections were applied separately for each performance metric (AUROC, recall, specificity) and each clinical outcome (AF, AKI, delirium, AMI, stroke, SSI), as these represent distinct groups of clinical hypotheses. A post-hoc assessment of sample size was made for each outcome-feature set combination with reference to guidelines on required sample size for predictive modelling (Supplementary Methods 5) [23].

Analyses were performed in Python (3.6.8) with scikit-learn (0.24.2) and imbalanced-learn (0.8.1) for preprocessing, Elastic Net and Balanced Bagging Classifier models, tensorflow/keras (2.6.2) for autoencoder classes, and scipy.stats (1.5.4) and statsmodels (0.12.2) for model evaluation.

Results

The UK Biobank dataset contained 158,156 individuals undergoing qualifying surgery of whom 4743 had omic data available and experienced at least one of the postoperative complications of interest (Table 2). The numbers of individuals with each postoperative complication, and the subsets with metabolomic, proteomic and both datasets, are shown in Supplementary Table 1 with assessment of sample size adequacy in Supplementary Table 2. For metabolomic data, case numbers ranged from 144 for AMI to 1596 for AKI; proteomics were available for between 27 and 289 cases; and multiomic data were present for between 15 and 219 individuals. The median (IQR [range]) time between sampling and surgery was 6 (2.9–9.4 [1 day – 15.5]) years.

Distinct baseline models were trained for the subset of participants who had available data for each of the omic feature sets. Overall performance of the baseline models was good, though feature sets with smaller sample sizes (multiomics) tended to show greater variability (Figure 2, Panels A–F).

Baseline models trained in the subset of participants with metabolomic data achieved good performance with AUROC ranging from 0.72 (+/- 0.02) to 0.88 (+/- 0.02) and sensitivity from 0.71 (+/- 0.06) to 0.78 (+/- 0.02). Across all outcomes, adding metabolomic features to the baseline clinical models did not produce clinically-meaningful improvements in any performance metrics. Delirium and AF showed the best performance with models for SSI tending to show the worst performance (Figure 2, Panels A–F; Supplementary Tables 3.1–3.6). Results for the AMI metabolomic model showed greater variability which is reflective of the sample size being below recommended levels (Supplementary Table 2).

In the proteomic cohort, baseline clinical models performed well for AF, AKI and delirium (AUROC 0.81–0.85; sensitivity 0.71–0.80) and performance was not improved by the addition of proteomic features (Figure 2, Panels A–C; Supplementary Tables 3.1–3.3). Models for SSI tended to perform least well (AUC 0.71–0.72, sensitivity 0.74–0.79) though specificity was improved by the addition of proteomic features (inflammation I 0.64 (+/- 0.02) vs 0.7 (+/- 0.01), inflammation I+II

0.64 (+/- 0.01) vs 0.69 (+/- 0.01), all proteins 0.64 (+/- 0.01) vs 0.68 (+/- 0.01), all $p < 0.001$ for corrected resampled t-test comparing 60 cross-validation folds; Figure 2, Panel D, Supplementary Table 3.5). Sample sizes for stroke and AMI were less than 33% of recommended levels (Supplementary Table 2) so were not considered further for proteomic modelling.

In the multiomic cohort, baseline models for AF and AKI showed good performance (AUC 0.81–0.85, sensitivity 0.71–0.77, specificity 0.75–0.76) and were not improved by the addition of multiomic features by early integration (Figure 2, Panel A–B; Supplementary Tables 3.1–3.2). Sample sizes for the other outcomes and for all outcomes using the late integration approach were substantially lower than recommended levels so not considered further (Supplementary Table 2).

Case numbers for the transfer learning paired phenotypes were between 3.4 and 12.5 times those of the target (postoperative) cohort, depending on phenotype and feature set (Supplementary Table 4).

The metabolomic dataset had the largest sample size for every outcome studied, meeting sample size recommendations for all except AMI (Supplementary Table 2). For AMI, transfer learning tended to improve model performance and reduce the variability of predictions, though no metrics showed statistically significant improvements across the cross-validation procedure (Figure 2, Panel E; Supplementary Table 3.4). For SSI, where an alternative diagnosis was used, transfer learning resulted in reduced sensitivity compared to baseline and direct learning models (transfer model 0.64 +/- 0.04, baseline 0.75 +/- 0.03, $p < 0.001$; direct 0.72 +/- 0.03, $p = 0.01$, across 60 cross-validation folds) (Figure 2, Panel D, Supplementary Table 3.5).

For proteomic feature sets, sample sizes were below recommended levels for all outcomes except AKI and AF (Supplementary Table 2). Transfer learning tended to result in improved stability compared to models trained in the postoperative cohort but performance was similar (Figure 2, Panels C–F; Supplementary Tables 3.3–3.6).

For transfer models using multiomic feature sets (early integration), model stability was generally improved by transfer learning compared to models learned directly from the postoperative dataset, particularly for AMI and stroke, but did not result in statistically significant performance gains over clinical baseline models (Figure 2, Panels A–F; Supplementary Tables 3.1–3.6).

Discussion

In this large-scale analysis of the UK Biobank cohort, we report that the addition of high-dimensional metabolomic and proteomic data to standard clinical variables produced no incremental benefit in predicting a broad range of postoperative complications (atrial fibrillation, acute kidney injury, delirium, acute myocardial infarction, surgical site infection and stroke). These findings remained consistent across six distinct clinical phenotypes, single- and multiomic datasets and multiple statistical approaches. We also found that transfer learning from non-postoperative to postoperative domains produced good model performance whilst countering the limitations of small sample sizes.

A likely explanation for the observed lack of benefit with additional omic data is the temporal resolution of the assays. Metabolomic and proteomic assays provide dynamic snapshots of physiological homeostasis, reflecting the interplay between intrinsic and environmental factors [8]. In the UK Biobank cohort studied, samples for these assays were obtained at a variable time interval from the operative event, with a median interval of six years between sampling and surgery. They therefore did not necessarily reflect the physiological reserve available to withstand the inflammatory insult of a particular surgical episode [24]. For these biomarkers to add predictive value in the peri-operative setting, they may need to be measured closer to the time of surgery to capture the immediate physiological context.

The robust predictive power of the baseline clinical models suggests that much of the biological signal needed to risk-stratify patients is captured by macroscopic, phenotypic data and raises an important consideration regarding the lead-time of multiomic data. Whilst historic omic profiles may capture latent, undiagnosed pathology that more accurately reflects an individual's true underlying multi-morbidity, any potential predictive advantage is likely attenuated by the interval between sampling and surgery. Subclinical trajectories identified by the omic 'snapshot' may have progressed to manifest clinical disease over this period and thus be recorded as comorbidities. This contrasts with studies in the non-surgical setting, where omic assays in biobank samples have successfully predicted long-term chronic disease risk [10,11]. In those instances, omics are used to predict future

onset of disease, whereas in this study we are essentially looking backwards using clinical records at the time of surgery in which progression to diagnosis has already occurred.

To address the constraints of modelling rare events with high-dimensional inputs and limited sample sizes, we applied transfer learning from the non-postoperative domain. This resulted in improved performance relative to the models trained in the original target domain, particularly in terms of model stability (as would be expected with a larger effective sample size). From a biological perspective, the success of this transfer learning suggests that the paired postoperative and non-postoperative phenotypes have a shared underlying architecture of clinical and omic risk factors. The systemic inflammatory stress of major surgery may therefore accelerate the appearance of a phenotype in an individual with biological predisposition: rather than representing *de novo* pathologies in the postoperative period, these complications may represent an acute unmasking of latent vulnerabilities in at-risk individuals. Whether these phenotypes would have become manifest without surgery as a 'trigger' cannot be determined from these analyses. Of note, we used an alternative diagnosis as the source domain for SSI and saw decreased sensitivity when predicting the postoperative outcome. This highlights the limitations of the approach and the importance of selecting an appropriate context from which to transfer learning.

From a translational perspective, these findings support the principle of parsimony in pre-operative assessment and risk stratification. Existing scoring systems based on demographic and clinical inputs are easily accessible, resource-efficient and interpretable. The performance of our baseline models was comparable to, or exceeded, that of other widely used risk scores for morbidity or complications [25,26]. Our data suggest that the cost and logistical complexity of additional high-throughput omics collected at a temporal distance from surgery are not currently justified. However, it remains possible that omic data would provide significant incremental benefit if measured in the immediate peri-operative period, capturing acute preclinical physiological decline that has not yet resulted in a formal diagnosis. Further research should explore this approach as a means of deriving benefit from the additional resolution these assays provide.

Strengths of this study include the use of a large, deeply-phenotyped cohort and a rigorous methodological pipeline to prevent data leakage, reduce the risk of overfitting and provide unbiased estimates of model performance. Additionally, by evaluating distinct outcome phenotypes across organ systems we demonstrated that the lack of positive findings was not outcome-specific. However, the study does have limitations. The UK Biobank cohort are not representative of the wider population due to a ‘healthy volunteer’ bias [27], which may affect generalisability. Postoperative outcomes were derived from clinical coding data and were not prospectively screened for, so underreporting is likely. Some clinical variables which are widely used in existing risk prediction tools are not present in the linked healthcare data (e.g. ASA physical status grade, type of anaesthesia, surgical urgency) and so could not be included. Finally, despite the large overall size of the UK Biobank cohort, the sample size for the specific outcomes studied and the fact that only a proportion of individuals had omic profiling limited our statistical power to detect small effect sizes.

Overall, this study does not support the use of metabolomic or proteomic data measured at a temporal distance from surgery for pre-operative risk stratification. Standard clinical variables remain robust in this setting and the additional time, cost and complexity of omics profiling is not justified. However, given the success of the transfer learning approach employed, future work using larger cohorts of non-postoperative patients may produce insights which can be applied to the peri-operative setting. Alternatively, multiomic sampling closer to the surgical event may add additional benefit as it can capture the immediate physiological context in which the inflammatory insult of major surgery occurs.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 128619. This includes linked data provided by patients and collected by the NHS as part of their care and support and data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). This work was carried out using the computational and data storage facilities of the Advanced Computing Research Centre, University of Bristol (http://www.bristol.ac.uk/acrc/).

This study was funded by a Wellcome Trust GW4-CAT PhD Programme for Health Professionals PhD Fellowship awarded to RAA [316275/Z/24/Z]. RAA, PY, GMK and TRG are supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (RA, TG: MC_UU_00032/3; PY: MC_UU_00032/4; GMK: MC_UU_0032/6). GMK acknowledges additional funding from the Wellcome Trust (grant numbers: 201486/Z/16/Z and 201486/B/16/Z), the Medical Research Council (grant numbers: MR/W014416/1; MR/S037675/1; MR/Z50354X/1; and MR/Z503745/1. BG, TRG, GMK and PY are also supported by the UK National Institute for Health and Care Research (NIHR) Bristol Biomedical Research Centre (grant number: NIHR 203315). The views expressed are those of the authors and not necessarily those of the UK NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

TRG receives funding from GlaxoSmithKline, Biogen, Novartis and Roche for unrelated research. No other competing interests declared.

The source data for these analyses are available from UK Biobank. Details of how to access UK Biobank data can be found here: https://www.ukbiobank.ac.uk/use-our-data/apply-for-access/. Author-generated code to support the manuscript will be

publicly available on GitHub on publication (github.com/raarmstrong; DOI to be confirmed).

References

1. Dobson GP. Trauma of major surgery: A global problem that is not going away. *Int. J. Surg. Lond. Engl.* 2020; **81**: 47–54. https://doi.org/10.1016/j.ijsu.2020.07.017.

2. Albini A, Malavasi VL, Vitolo M et al. Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. *Eur. J. Intern. Med.* 2021; **85**: 27–33. https://doi.org/10.1016/j.ejim.2020.12.018.

3. Corredor C, Thomson R, Al-Subaie N. Long-Term Consequences of Acute Kidney Injury After Cardiac Surgery: A Systematic Review and Meta-Analysis. *J. Cardiothorac. Vasc. Anesth.* 2016; **30**: 69–75. https://doi.org/10.1053/j.jvca.2015.07.013.

4. Rudolph JL, Marcantonio ER. Postoperative Delirium: Acute Change with Long-Term Implications. *Anesth. Analg.* 2011; **112**: 1202. https://doi.org/10.1213/ANE.0b013e3182147f6d.

5. Protopapa KL, Simpson JC, Smith NCE, Moonesinghe SR. Development and validation of the surgical outcome risk tool (SORT). *Br. J. Surg.* 2014; **101**: 1774–83.

6. American College of Surgeons National Surgical Quality Improvement Programme. About the ACS risk calculator. https://riskcalculator.facs.org/RiskCalculator/about.html (accessed 07/01/2026).

7. Shaw A. Exploring the perioptome: the role of genomics in thoracic surgery and anaesthesia. *Curr. Opin. Anesthesiol.* 2007; **20**: 32. https://doi.org/10.1097/ACO.0b013e32801271e4.

8. Scarpa JR, Elemento O. Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review. *Br. J. Anaesth.* 2023; **131**: 26–36. https://doi.org/10.1016/j.bja.2023.03.006.

9. Verdonk F, Einhaus J, Tsai AS et al. Measuring the human immune response to surgery: multiomics for the prediction of postoperative outcomes. *Curr. Opin. Crit. Care* 2021; **27**: 717–25. https://doi.org/10.1097/MCC.0000000000000883.

10. Buergel T, Steinfeldt J, Ruyoga G et al. Metabolomic profiles predict individual multidisease outcomes. *Nat. Med.* 2022; **28**: 2309–20. https://doi.org/10.1038/s41591-022-01980-3.

11. Carrasco-Zanini J, Pietzner M, Davitte J et al. Proteomic signatures improve risk prediction for common and rare diseases. *Nat. Med.* 2024; **30**: 2489–98. https://doi.org/10.1038/s41591-024-03142-z.

12. Picard M, Scott-Boyer M-P, Bodein A, Périn O, Droit A. Integration strategies of multi-omics data for machine learning analysis. *Comput. Struct. Biotechnol. J.* 2021; **19**: 3735–46. https://doi.org/10.1016/j.csbj.2021.06.030.

13. Zhu Y, Brettin T, Evrard YA et al. Ensemble transfer learning for the prediction of anti-cancer drug response. *Sci. Rep.* 2020; **10**: 18040. https://doi.org/10.1038/s41598-020-74921-0.

14. UK Biobank. Resource 4654: Olink proteomics data. https://biobank.ndph.ox.ac.uk/ukb/refer.cgi?id=4654 (accessed 21/11/2025).

15. UK Biobank. Category 220: NMR metabolomics. https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=220 (accessed 21/11/2025).

16. Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of surgical treatment and related hospital procedures in the UK: a national ecological study using hospital episode statistics. *BJA Br. J. Anaesth.* 2017; **119**: 249–57. https://doi.org/10.1093/bja/aex137.

17. Bupa. Schedule of procedures. https://codes.bupa.co.uk/procedures (accessed 12/05/2021).

18. Armstrong RA, Yousefi P, Gibbison B, Khandaker GM, Gaunt TR. The genetic architecture of postoperative delirium after major surgery and its relationship with non-postoperative neurocognitive conditions. *PLOS Med.* 2026; **In press**.

19. Gleason LJ, Schmitt EM, Kosar CM et al. Effect of Delirium and Other Major Complications on Outcomes After Elective Surgery in Older Adults. *JAMA Surg.* 2015; **150**: 1134–40. https://doi.org/10.1001/jamasurg.2015.2606.

20. Richardson DB. An incidence density sampling program for nested case-control analyses. *Occup. Environ. Med.* 2004; **61**: e59. https://doi.org/10.1136/oem.2004.014472.

21. Corbin L, Hughes D, Sunderland N, Lee M, McKinlay A. metaboprep: metabolomics data preparation and processing pipeline. 2025. https://github.com/MRCIEU/metaboprep (accessed 21/11/2025).

22. Nadeau C, Bengio Y. Inference for the Generalization Error. *Mach. Learn.* 2003; **52**: 239–81. https://doi.org/10.1023/A:1024068626366.

23. Riley RD, Ensor J, Snell KIE et al. Calculating the sample size required for developing a clinical prediction model. *BMJ* 2020; **368**: m441. https://doi.org/10.1136/bmj.m441.

24. Seymour KA, Strain M, Ashley-Koch A et al. Acute perioperative alterations in metabolism: A pilot study using mass spectrometry–based metabolomics. *Surgery* 2025; **180**: 109055. https://doi.org/10.1016/j.surg.2024.109055.

25. Bilimoria KY, Liu Y, Paruch JL et al. Development and Evaluation of the Universal ACS NSQIP Surgical Risk Calculator: A Decision Aid and Informed Consent Tool for Patients and Surgeons. *J. Am. Coll. Surg.* 2013; **217**: 833. https://doi.org/10.1016/j.jamcollsurg.2013.07.385.

26. Wong DJN, Oliver CM, Moonesinghe SR. Predicting postoperative morbidity in adult elective surgical patients using the Surgical Outcome Risk Tool (SORT). *Br. J. Anaesth.* 2017; **119**: 95–105. https://doi.org/10.1093/bja/aex117.

27. Fry A, Littlejohns TJ, Sudlow C et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the

General Population. *Am. J. Epidemiol.* 2017; **186**: 1026–34. https://doi.org/10.1093/aje/kwx246.

Table 1 Feature sets used in direct postoperative modelling

Model	**Clinical Covariates**	**Metabolomic Data**	**Proteomic Data**
Baseline	X		
+ metabolomics	X	X	
+ proteomics: Inflammation I	X		Olink Inflammation Panel I
+ proteomics: Inflammation I+II	X		Olink Inflammation Panels I+II
+ proteomics: all proteins	X		All Olink Proteins
+ multiomic (Inflammation I)	X	X	Olink Inflammation Panel I
+ multiomic (Inflammation I+II)	X	X	Olink Inflammation Panels I+II
+ multiomic (all proteins)	X	X	All Olink Proteins

Table 2 Participant characteristics of individuals undergoing major surgery in UK Biobank with available metabolomic and/or proteomic data. Values are mean (SD), median (IQR [range]) or number (proportion).

Characteristic	**Controls** n = 87,458	**Cases*** n = 4743	**p-value**
Age; y	65 (8)	71 (7)	<0.001
Sex; female	48,702 (56%)	2065 (44%)	<0.001
Ethnicity			0.081
Asian or Asian British	1335 (1.5%)	51 (1.1%)	
Black or Black British	987 (1.1%)	53 (1.1%)	
Mixed	408 (0.5%)	21 (0.4%)	
Other ethnic group	775 (0.9%)	29 (0.6%)	
Prefer not to answer	271 (0.3%)	14 (0.3%)	
White	83,603 (96%)	4566 (96%)	
Missing	79 (<0.1%)	9 (0.2%)	
Charlson Comorbidity Index	0 (0–1 [0–15])	1 (0–2 [0–14])	<0.001
Admission method; emergency	19,070 (22%)	2279 (48%)	<0.001
Operative category; complex	11,086 (13%)	617 (13%)	0.5
Surgical specialty			<0.001
Cardiothoracic surgery	3917 (4.5%)	125 (2.6%)	
General surgery	15,832 (18%)	1262 (27%)	
Neurosurgery	3066 (3.5%)	284 (6.0%)	

Characteristic	Controls n = 87,458	Cases* n = 4743	p-value
Other	56,781 (65%)	2379 (50%)	
Urology	6724 (7.7%)	418 (8.8%)	
Vascular surgery	1138 (1.3%)	275 (5.8%)	
Postoperative complications			
Acute kidney injury	N/A	1745 (37%)	
Acute myocardial infarction	N/A	159 (3.4%)	
Atrial fibrillation	N/A	1564 (33%)	
Delirium	N/A	562 (12%)	
Stroke	N/A	360 (7.6%)	
Surgical site infection	N/A	904 (19%)	
Available omic datasets			
Metabolomic data	80,776 (92%)	4392 (93%)	0.6
Proteomic data	15,843 (18%)	898 (19%)	0.14
Multiomic data	9161 (10%)	547 (12%)	0.023

Individuals who were present as both cases and controls (for different outcomes) are included under cases. Individuals who were cases or controls for multiple outcomes are included only once, taking their characteristics at the first occurrence.

Figure captions

Figure 1 Schematic representation of study pipeline. Direct postoperative modelling (blue) represents using the surgical UK Biobank cohort to train predictive models based on the postoperative outcomes of interest. Transfer learning (green) represents using the non-surgical UK Biobank cohort to train predictive models based on the non-postoperative equivalent outcome phenotypes. The surgical cohort are then passed through the non-surgical model and a predicted risk for the non-surgical outcome is used as a feature in a transfer model to predict the postoperative outcome (orange).

Figure 2 Evaluation metrics for each postoperative complication and feature set. Baseline models (grey circles ●); omics models (blue squares ■); transfer models (red diamonds ◆). Values are mean with standard deviation error bars. AUC: area under the receiver operator characteristic curve.


Direct postoperative modelling
Transfer learning
Surgical cohort
Clinical data
+
Omic data
Training
Baseline model
Baseline + omics model
Transfer model
Prediction
Non-surgical cohort
Clinical data
+
Omic data
Training
Non-surgical model
Prediction
Non-postoperative outcomes
Training
Postoperative outcomes
AF
AKI
AMI
Delirium
SSI
Stroke
Evaluation


A. Atrial fibrillation
B. Acute kidney injury
C. Delirium
D. Surgical site infection
E. Acute myocardial infarction
F. Stroke
Metabolomics
Inflammation I
Inflammation I+II
All Proteins
Multiomic (Infl I)
Multiomic (Infl I+II)
Multiomic (All Prot)
AUC
Sensitivity
Specificity